At BioAgilytix, growth is fueled by opportunity, collaboration, and the people around us. Christopher Gomes, Analyst III, shares how his transition from academia has allowed him to work on diverse projects, expand his expertise, and grow alongside a talented team that values both professional development and employee appreciation.
Moving an antibody program from preclinical development to IND submission requires more than strong science. It requires a bioanalytical strategy designed to support informed decisions at every stage. At the PBSS Antibody Preclinical Development & IND Filing conference in South San Francisco, BioAgilytix scientist Liz Nolff presented "Streamlined Preclinical Bioanalytical Strategies: Accelerate to IND," highlighting approaches that can help sponsors efficiently generate the data needed to advance their programs. The presentation also explored the role of generic PK methods in supporting antibody IND submissions and how strategic assay planning can help reduce risk and accelerate timelines. What bioanalytical considerations have had the biggest impact on your IND preparation strategy?
Making the transition from academia to industry can feel like a big leap — but at #BioAgilytix, it’s also an exciting opportunity to grow.
